Black checkmark with a sparkle and a curved line underneath on a white background.
Company

Modular Medical, Inc.

Ticker
MODD
Sector
Industry
Report date
November 16, 2026
Valye AI Score

94

Very high visibility
Recent developments
Recent developments summary

Recent developments include leadership changes, commercial rollout of the Pivot insulin patch pump, FDA clearance for software enhancements, and securing a national PBM contract to expand product access.

Recent developments:
  • Modular Medical reported the resignation of Duane DeSisto and results of the Fiscal 2027 Annual Meeting [N1].
  • The company secured a national pharmacy benefits manager contract to expand access to its Pivot insulin patch pump [N3].
  • The Pivot insulin patch pump received FDA clearance for software enhancements [N5].
  • Initial commercial shipments of the Pivot insulin delivery system began in the United States, with rollout activities ongoing [N8].
  • Modular Medical was highlighted among biotech movers with stock price jumps and increased market attention [N2].
Overview

Modular Medical, Inc. develops and commercializes insulin pumps aimed at increasing adoption in the diabetes market by addressing cost, complexity, and usability challenges of existing devices. The company’s flagship product, the Pivot insulin patch pump, is a tubeless, reusable, and easy-to-use device designed to serve both Type 1 and Type 2 diabetes patients requiring multiple daily insulin doses. The Pivot system features a reusable pump combined with disposable cartridges and sets, a simple one-button interface, and optional smartphone software. The company received FDA clearance for Pivot in April 2026 and commenced initial US commercial shipments in June 2026, with plans to expand geographically and obtain CE mark clearance for Europe and other markets. Modular Medical targets the large segment of insulin-requiring patients who currently rely on multiple daily injections due to barriers with existing pumps, aiming to increase market penetration by overcoming usability, affordability, accessibility, and support hurdles. The company’s financial position as of September 30, 2026 shows limited cash resources and ongoing net losses, with a need for additional financing to sustain operations.

Executive summary

Modular Medical, Inc. is a medical device company specializing in innovative insulin pumps designed to simplify use and expand adoption among insulin-requiring diabetes patients. Its next-generation Pivot patch pump received FDA clearance in April 2026 and began commercial shipments in June 2026 in the US, with plans for broader market expansion and international regulatory clearance. The company targets a large market segment of patients currently underserved by existing insulin pump technology due to cost, complexity, and usability barriers. Financially, as of September 30, 2026, Modular Medical reported $5.1 million in cash and equivalents, a net loss of $7.1 million for the quarter, and faces substantial doubt about its ability to continue as a going concern without additional capital. Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice.

Scenarios for MODD

Bull case model:

The company’s innovative Pivot insulin patch pump addresses significant barriers to insulin pump adoption by simplifying use, reducing cost, and improving patient experience. FDA clearance and initial commercial shipments in the US mark important milestones toward market penetration. Securing a national PBM contract facilitates easier insurance reimbursement, potentially accelerating adoption. The large addressable market of insulin-requiring diabetes patients, particularly those currently using multiple daily injections, represents a substantial opportunity. Continued product enhancements, regulatory approvals in international markets, and effective commercialization efforts could support broader adoption and revenue growth.

Bear case model:

Modular Medical faces significant financial risks, including substantial doubt about its ability to continue as a going concern without additional capital. The company has reported ongoing net losses and limited cash reserves, which may constrain its ability to fund operations and commercial expansion. Market adoption of the Pivot pump depends on overcoming entrenched patient and provider preferences, insurance reimbursement complexities, and competition from established insulin pump manufacturers. Regulatory and manufacturing challenges could delay product availability or increase costs. Failure to secure sufficient financing or achieve commercial traction could materially impact the company’s viability and shareholder value.

Moat:

Modular Medical’s moat is based on its proprietary insulin pump technology that addresses key shortcomings of existing pumps, including complexity, cost, and usability. Its Pivot patch pump offers a reusable, tubeless design with a simplified user interface and integrated software, differentiating it from traditional bulky and complex pumps. The company’s focus on overcoming insurance reimbursement hurdles through pharmacy benefits manager contracts and its targeted approach to the underserved 'Almost Pumpers' market segment further support its competitive positioning. Additionally, the company’s intellectual property, including patents on its pairing technology, and its clinical and regulatory progress contribute to barriers for competitors.

Risks overview
Risks summary
The most significant risk is the company’s substantial doubt about its ability to continue as a going concern without additional capital, which could affect its operational continuity and shareholder value.
Risks details:

• Going Concern Risk: The company has substantial doubt about its ability to continue as a going concern due to limited cash resources and ongoing operating losses, requiring additional financing to sustain operations [S2].
• Market Adoption Risk: Adoption of the Pivot insulin pump depends on overcoming patient, provider, and insurance barriers in a market with established competitors and complex reimbursement dynamics [S1].
• Regulatory and Manufacturing Risk: Delays or challenges in obtaining regulatory clearances, manufacturing scale-up, or product quality issues could impact commercial availability and costs [S1].
• Financial Risk: The company’s need to raise additional capital may result in dilution of existing shareholders or unfavorable financing terms [S2].

FINAL FORECAST FOR MODD

Final take one line
Modular Medical is advancing its innovative insulin patch pump commercialization amid financial challenges requiring additional capital.
Final take 12 to 24 month view

Business trends: Expansion of insulin pump adoption through simplified, affordable technology targeting underserved diabetes patients; increasing commercial rollout of the Pivot patch pump.
Execution milestones: FDA clearance and initial US commercial shipments of Pivot; securing national PBM contract; planned CE mark clearance for Europe.
Key risks: Financial sustainability concerns due to cash burn and need for capital; market adoption barriers; regulatory and manufacturing challenges.

Valye AI Visibility Research Score

Very high visibility

Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).

94
LLM visibility overview
LLM Visibility known facts
  • Modular Medical, Inc. is a medical device company focused on designing, developing, and commercializing innovative insulin pumps using modernized technology to increase pump adoption in the diabetes market [S1].
  • The company developed a two-part patch pump system intended to simplify insulin delivery and expand the market beyond highly motivated users to a broader mass market, targeting both Type 1 and Type 2 diabetes patients requiring multiple daily insulin doses [S1].
  • The initial product, MODD1, received FDA clearance in September 2024 but is not intended for commercialization [S1].
  • The next-generation product, Pivot, is a tubeless insulin delivery patch pump integrating infusion set and pump, designed for cost and usability improvements and manufacturability [S1].
  • Pivot received FDA clearance in April 2026 and began commercial availability and initial shipments in the United States in June 2026, with plans to expand across metropolitan markets by late 2026 [S1].
  • The company intends to obtain CE mark clearance for Pivot by Q2 2027 to enable marketing in Europe and other international markets [S1].
  • Pivot features include a three-part system (one reusable, two disposable), one-button interface, optional phone software, 90-day reusable pump with 3-day disposable cartridge, removable system, no external controller or battery replacement, and a slim, lightweight profile [S1].
  • The company targets the large insulin-requiring diabetes market, including approximately 4.2 million potential insulin pump users split evenly between Type 1 and Type 2 diabetes in the US, with a focus on the 'Almost Pumpers' segment who currently use multiple daily injections due to cost, complexity, and usability barriers [S1].
  • The insulin pump market is estimated at approximately $1.9 billion currently, with a total addressable market of about $3 billion considering easier-to-use and reimbursable products [S1].
  • The company emphasizes overcoming adoption hurdles including usability, affordability, accessibility and education, and service and support to increase insulin pump adoption [S1].
  • Recent news highlights include the resignation of Duane DeSisto and results of the Fiscal 2027 Annual Meeting [N1].
  • Modular Medical secured a national pharmacy benefits manager (PBM) contract to expand access to the Pivot product [N3].
  • The Pivot insulin patch pump received FDA clearance for software enhancements [N5].
  • The company has begun the rollout of the Pivot pump commercially in the US [N8].
  • Financial snapshot as of September 30, 2026: cash and equivalents of $5.1 million, current assets of $5.86 million, current liabilities of $1.32 million, net loss of $7.1 million for the quarter, basic and diluted EPS of -$0.9, current ratio of 4.46, and cash ratio of 3.88 [S2].
  • The company has an accumulated deficit of $126.6 million as of September 30, 2026, and has raised capital through stock offerings in 2026 but expects to require additional financing to fund operations beyond 12 months from the report date [S2].
  • The company faces risks including substantial doubt about its ability to continue as a going concern without additional capital, which may impact its operations and stockholder value [S2].
Sources
Sources - Context summary

Generated 2026-11-17

Sources - Earning calls
Sources - Other context
Sources - SEC Filings
  • S1 | 2026-06-29 | 10-K
  • S2 | 2026-11-16 | 10-Q
Sources - News headlines
  • N1 | 2026-10-29 | www.nasdaq.com | Modular Medical, Inc. Reports Resignation of Duane DeSisto and Results of Fiscal 2027 Annual Meeting | https://www.nasdaq.com/articles/modular-medical-inc-reports-resignation-duane-desisto-and-results-fiscal-2027-annual
  • N2 | 2026-09-09 | www.nasdaq.com | Biotech Movers: Modular Medical Jumps, InnovAge Revenue Up 16%, Pyxis Data On Deck, Dogwood In Focus | https://www.nasdaq.com/articles/biotech-movers-modular-medical-jumps-innovage-revenue-16-pyxis-data-deck-dogwood-focus
  • N3 | 2026-09-08 | www.nasdaq.com | Modular Secures National PBM Contract To Expand Pivot Access | https://www.nasdaq.com/articles/modular-secures-national-pbm-contract-expand-pivot-access
  • N4 | 2026-09-04 | www.nasdaq.com | 5 Biotech And Medical Device Stocks In Focus: Pro-Dex, Modular Medical, ENvue Medical & More | https://www.nasdaq.com/articles/5-biotech-and-medical-device-stocks-focus-pro-dex-modular-medical-envue-medical-more
  • N5 | 2026-09-04 | www.nasdaq.com | Modular Medical's Pivot Insulin Patch Pump Gets FDA Clearance For Software Enhancements | https://www.nasdaq.com/articles/modular-medicals-pivot-insulin-patch-pump-gets-fda-clearance-software-enhancements
  • N6 | 2026-09-04 | www.nasdaq.com | 6 Biotech Stocks In Focus: Modular Medical, Galmed, Pro-Dex, Connect Biopharma & More | https://www.nasdaq.com/articles/6-biotech-stocks-focus-modular-medical-galmed-pro-dex-connect-biopharma-more
  • N7 | 2026-09-02 | www.nasdaq.com | 6 After-Hours Healthcare Gainers: Universe Pharma, BioAffinity, Modular Medical, Telix Pharma & More | https://www.nasdaq.com/articles/6-after-hours-healthcare-gainers-universe-pharma-bioaffinity-modular-medical-telix-pharma
  • N8 | 2026-08-21 | www.nasdaq.com | After-hours Gainers: HOWL Jumps 90%, MODD To Begin Pivot Pump Rollout, BIVI Awaits Long COVID Data | https://www.nasdaq.com/articles/after-hours-gainers-howl-jumps-90-modd-begin-pivot-pump-rollout-bivi-awaits-long-covid
Important legal disclaimer

This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Blue logo with a stylized checkmark and star above the blue text 'VALYE' on a black background.

Generated by Valye SEC Pipeline Engine